/stocks — the workspaceLOADING
All BJDX SEC filings, by type → · Earnings date & implied move · Search inside filings
BJDX is not among the 142 companies we ingest every day, so it is not in the fundamentals screener or the size and group lists built from it. This page reads its SEC filings when the page is built. Ask us to add it: we keep a count per ticker and nothing about you.
Latest report (10-Q, filed 2026-08-12). Three months to 2026-06-30 against 2025-06-30: Net loss $2.3M, 18.8% larger than $2.0M. Six months to 2026-06-30 against 2025-06-30: Operating cash used $3.1M, 4.6% smaller than $3.2M. Read it line by line, each linked to its source → · Every report →
Bluejay Diagnostics, Inc. (BJDX) is a surgical & medical instruments & apparatus company. 5 insider Form 4 filings in the last 90 days. Next earnings projected around 2027-03-05 from BJDX's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
Every filed figure on this page is free to read, dated and sourced; no column is held back for a paid plan. Each section with figures says what date they are true as of and where they come from.
What’s behind BJDX’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has BJDX been issuing shares? Offering history →
Volume against its own history: 63% of its last 252 sessions were lighter than the last one, the 2026-11-09 session. End-of-day bars (Databento). Volume detail
| Free cash flow per share | That year | Year before, same report | Change | Report |
|---|---|---|---|---|
| fiscal 2025 | -13.87 USD | -177.27 USD | not a growth rate (a year at or below zero) | 10-K filed 2026-03-06 |
| fiscal 2024 | -44.31 USD | -3290.05 USD | not a growth rate (a year at or below zero) | 10-K filed 2025-03-31 |
| fiscal 2023 | -8.22 USD | -8.87 USD | not a growth rate (a year at or below zero) | 10-K filed 2024-03-28 |
| fiscal 2022 | -0.44 USD | -0.52 USD | not a growth rate (a year at or below zero) | 10-K filed 2023-03-20 |
Concepts read: (us-gaap:NetCashProvidedByUsedInOperatingActivities - us-gaap:PaymentsToAcquirePropertyPlantAndEquipment) / us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
| Diluted EPS | That year | Year before, same report | Change | Report |
|---|---|---|---|---|
| fiscal 2025 | -15.25 USD | -456.75 USD | not a growth rate (a year at or below zero) | 10-K filed 2026-03-06 |
| fiscal 2024 | -114.19 USD | -3631.48 USD | not a growth rate (a year at or below zero) | 10-K filed 2025-03-31 |
| fiscal 2023 | -9.08 USD | -9.22 USD | not a growth rate (a year at or below zero) | 10-K filed 2024-03-28 |
| fiscal 2022 | -0.46 USD | -0.41 USD | not a growth rate (a year at or below zero) | 10-K filed 2023-03-20 |
| fiscal 2021 | -0.41 USD | -0.37 USD | not a growth rate (a year at or below zero) | 10-K filed 2022-03-10 |
Concepts read: us-gaap:EarningsPerShareBasicAndDiluted; us-gaap:EarningsPerShareDiluted
Per filed share, as each report states it. Free cash flow per share is operating cash flow less capital expenditure, over the diluted weighted average share count (or net income over diluted EPS where the count is tagged per share class).
Each year’s change comes from one annual report, which states that year and the year before on the same share basis, and the rate compounds those changes; so a split or a restatement between reports cannot bend it. A rate needs a positive figure at both ends of its window. The DCF above grows total free cash flow and divides by today’s share count, so a per-share rate also carries the buybacks or new shares of those years. These are past figures, not a forecast.
Not shown yet: the P/E range BJDX has traded at, which would set the discount rate and terminal assumptions against its own history. It needs a long daily price history we are not yet licensed to display.
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from BJDX’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as BJDX tagged it: revenue us-gaap:Revenues, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on BJDX plus an auto-SWOT, built from BJDX's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts, a bull, a bear, a risk manager, and a PM, debate BJDX using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Ask about BJDX’s revenue, earnings, valuation, filings, insiders or Congress trades. Answers come only from the numbered evidence the research brief uses, each citing the items it rests on. A question about one figure is answered by code, free. One that puts figures together is 1 generation (Pro). A question about whether to buy, sell or hold, how much, or where the price goes gets a refusal.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Closes only, split-adjusted. An average needs that many sessions on file to print. These are measurements, not support, resistance or targets. Chart with studies
Daily closes from 2024-11-14 through 2026-11-09, 497 sessions, split-adjusted (4 splits applied), history before 2024-11-14 left out at a corporate action. No direction, pattern, entry, target or overbought label: these are measurements. Filings dated on the move days are in BJDX’s filings; the chart with studies draws every figure.
Written by code from 497 end-of-day bars through 2026-11-09. Written by code from the data on file, not by a model. Information, not investment advice: it describes the security and recommends nothing to anyone.
Projected from BJDX's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentBJDX files or announces.
| Reported | Close-to-close |
|---|---|
| 2026-05-07 | -9.0% |
| 2026-03-06 | -1.6% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
On file for BJDX from Nov 10, 2026 to Nov 23, 2026: filing deadline (below).
| Event | Result |
|---|---|
| Earnings date | nothing in the window. Nothing in the window. The next report is projected around Mar 5, 2027, after it. |
| Filing deadline | on file. In the window: the 10-Q for the quarter ending Sep 30, 2026, due 40 to 45 days after it as SEC states no filer status for it, the span covers every status, falls due between Nov 9, 2026 and Nov 16, 2026. Newest periodic report on file: the 10-Q for the period ending Jun 30, 2026, filed Aug 12, 2026. filing list on EDGAR |
| Ex-dividend date | not covered. Not checked. This attestation does not cover ex-dividend dates. |
This records what these sources returned when they were read. It is not a forecast: a company can announce an event at any time, and ex-dividend dates are not covered. Window 2026-11-10 to 2026-11-23, Eastern dates. Deadlines follow SEC Rules 13a-1 and 13a-13 and Form 20-F, moved past weekends and federal holidays by Rule 0-3.
2 of the 2 checks that ran found nothing new for BJDX. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
None of the 5 estimators could run on BJDX's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for BJDX. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for BJDX, so sector medians could not fill the gaps.
Every refusal recorded for BJDX → · How often we decline, and why →
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
Group: Surgical & Medical Instruments & Apparatus, the SEC industry code BJDX files under. 9 companies in our stored table file under it.
| Metric | BJDX | Group median | 25th to 75th percentile | Where BJDX sits |
|---|---|---|---|---|
| Net marginnet income divided by revenue, same fiscal year | not placed | 14.4%⊙INFERENCE — derived by arithmetic SourceNet margin across the 9 companies filing under SEC SIC "Surgical & Medical Instruments & Apparatus" in our stored table As offiscal years ended 2025-12-31 to 2026-06-30 HowEach company's net income divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. A group prints from 6 companies with the figure. | 12.9% to 23.1% | BJDX has no annual report in the stored table yet, so it has no figure to place. |
| Free cash flow marginoperating cash flow less capital expenditure, divided by revenue, same fiscal year | not placed | 18.2%⊙INFERENCE — derived by arithmetic SourceFree cash flow margin across the 9 companies filing under SEC SIC "Surgical & Medical Instruments & Apparatus" in our stored table As offiscal years ended 2025-12-31 to 2026-06-30 HowEach company's operating cash flow less capital expenditure, divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. A group prints from 6 companies with the figure. | 9.0% to 29.2% | BJDX has no annual report in the stored table yet, so it has no figure to place. |
| Return on equitynet income divided by stockholders’ equity at the fiscal year end | not placed | 14.5%⊙INFERENCE — derived by arithmetic SourceReturn on equity across the 9 companies filing under SEC SIC "Surgical & Medical Instruments & Apparatus" in our stored table As offiscal years ended 2025-12-31 to 2026-06-30 HowEach company's net income divided by stockholders’ equity at the fiscal year end, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. A group prints from 6 companies with the figure. | 9.5% to 23.1% | BJDX has no annual report in the stored table yet, so it has no figure to place. |
One filed metric per row, each a ratio of two figures from the same annual report; no composite and no grade. Percentile is the share of the group’s other companies with a lower figure. A group prints from 6 companies with the figure. The group is drawn from our stored table (the S&P 500 issuers and the companies we cover, each with its newest annual report read), not from every filer in the class. Industry pages show the same medians by group.
Head office: Acton, Massachusetts, United States · the company’s charter and its head office are in different states.
A charter change was filed after this. An 8-K filed 2026-11-04 reports an amendment to the company’s articles and a change to shareholder rights (Items 5.03 and 3.03). Reincorporations are reported that way, but so are routine changes such as a new series of preferred stock, and we have not read this one. If it moved the company, the next periodic report’s cover will show it.
Source: the cover page of Bluejay Diagnostics, Inc.’s 10-Q filed 2026-08-12, on EDGAR. Filings checked 2026-11-10. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
No tracked institution reported a position in BJDX in the latest 13F round.
Of 1 sale in the last ~6 months, 0 were filed with the Rule 10b5-1 box checked, set up in advance under a written trading plan; 1 was filed without it.
| HRT FINANCIAL LP10% owner | SELL | $49K | view → |
| HRT FINANCIAL LP10% owner | BUY | $97K | view → |
| Wurth Douglas ClarkDirector | BUY | $25K | view → |
| Dey IndranilPresident and CEO | BUY | $25K | view → |
| CHASE DONALD RDirector | BUY | $25K | view → |
| ZEIDMAN FRED SDirector | BUY | $25K | view → |
| Dey SvetlanaDirector | BUY | $25K | view → |
No lawmaker has disclosed a trade in BJDX under the STOCK Act.